Mesenchymal Stem Cell Insights: Prospects in Cardiovascular Therapy

ASIA unversity > 醫學暨健康學院 > 生物科技學系 > 期刊論文 > Item 310904400/86922

Please use this identifier to cite or link to this item: http://asiair.asia.edu.tw/ir/handle/310904400/86922

Title:	Mesenchymal Stem Cell Insights: Prospects in Cardiovascular Therapy
Authors:	Ch, Shiu-Huey;Chou, Shiu-Huey;林欣榮;郭薇雯;Pai, Peiying;Pai, Peiying;Li, Jing-Ying;Lin, Jing-Ying;La, Chao-Hung;Lai, Chao-Hung;郭家驊;林冠合;蔡輔仁;黃志揚;Huang, Chih-yang;*
Contributors:	生物科技學系
Date:	2014-04
Issue Date:	2014-11-07 06:51:06 (UTC+0)
Abstract:	Ischemic heart damage usually triggers cardiomyopathological remodeling and fibrosis, thus promoting the development of heart functional failure. Mesenchymal stem cells (MSCs) are a heterogeneous group of cells in culture, with multipotent and hypoimmunogenic characters to aid tissue repair and avoid immune responses, respectively. Numerous experimental findings have proven the feasibility, safety, and efficiency of MSC therapy for cardiac regeneration. Despite that the exact mechanism remains unclear, the therapeutic ability of MSCs to treat ischemia heart diseases has been tested in phase I/II clinical trials. Based on encouraging preliminary findings, MSCs might become a potentially efficacious tool in the therapeutic options available to treat ischemic and nonischemic cardiovascular disorders. The molecular mechanism behind the efficacy of MSCs on promoting engraftment and accelerating the speed of heart functional recovery is still waiting for clarification. It is hypothesized that cardiomyocyte regeneration, paracrine mechanisms for cardiac repair, optimization of the niche for cell survival, and cardiac remodeling by inflammatory control are involved in the interaction between MSCs and the damaged myocardial environment. This review focuses on recent experimental and clinical findings related to cellular cardiomyoplasticity. We focus on MSCs, highlighting their roles in cardiac tissue repair, transdifferentiation, the MSC niche in myocardial tissues, discuss their therapeutic efficacy that has been tested for cardiac therapy, and the current bottleneck of MSC-based cardiac therapies.
Relation:	CELL TRANSPLANTATION;23(4-5):513-29.
Appears in Collections:	[生物科技學系] 期刊論文

Files in This Item:

File	Size	Format
index.html	0Kb	HTML	466	View/Open

Loading...